Oncology Business Management | Specialty

FDA Priority Review Granted to Carfilzomib sNDA in Myeloma

March 30th 2015

An sNDA for the full approval of carfilzomib (Kyprolis) as a treatment for patients with relapsed multiple myeloma has been granted a priority review by the FDA.

Patricia Hofstra on Alternatives to Acquisition in Healthcare

March 25th 2015

Patricia Hofstra, attorney, Duane Morris, discusses options that independent oncology groups have other than being acquired by larger healthcare or oncology systems.

Report Calls for Drug Pricing Reforms

March 16th 2015

A new report has called for broad changes in the way drugs are priced in the United States, saying the law of supply and demand is not doing an effective job of bringing the cost of cancer drugs down to a level comparable with other countries.

FDA Approves Dinutuximab for High-Risk Neuroblastoma

March 10th 2015

The FDA has approved dinutuximab in combination with interleukin-2, GM-CSF, and 13-cis-retinoic acid as a frontline therapy for pediatric patients with high-risk neuroblastoma.

FDA Approves Zarxio as First US Biosimilar

March 6th 2015

The FDA has approved its first biosimilar, Zarxio, for all five its counterpart Neupogen's authorized indications.

FDA Approves Nivolumab for Lung Cancer

March 4th 2015

Acting 3 months ahead of schedule, the FDA approved nivolumab (Odivo) for patients with squamous non-small cell lung cancer.

FDA Grants Rindopepimut Breakthrough Designation for EGFRvIII-Positive Glioblastoma

February 23rd 2015

Rindopepimut (Rintega) has gained a Breakthrough Therapy Designation from the FDA to treat adult patients with glioblastoma multiforme that test positive for the epidermal growth factor receptor variant.

Immunotherapy, Personalized Medicine to Highlight Winter Hematology Meeting

February 20th 2015

Oncologists, hematologists, and other experts on hematologic malignancies will convene for the 19th Annual International Congress on Hematologic Malignancies, from February 20-21 in Miami, Florida, to provide insight into recent developments in the treatment of the diseases.

Cobimetinib Receives Priority Review for Advanced Melanoma

February 19th 2015

The FDA has granted a priority review to the MEK inhibitor cobimetinib for use in combination with the BRAF inhibitor vemurafenib (Zelboraf) to treat patients with BRAF V600–positive advanced melanoma.

FDA Approves Frontline Revlimid for Multiple Myeloma

February 18th 2015

The FDA has approved lenalidomide (Revlimid) plus dexamethasone in newly diagnosed patients with multiple myeloma based on findings from the phase III FIRST trial.

Tulane Cancer Center and Its World-Class Teams Join Onclive in Strategic Alliance Partnership Program

February 17th 2015

OncLive and Tulane Cancer Center at the Tulane University School of Medicine have joined forces to promote awareness of new developments in cancer care through OncLive's Strategic Alliance Partnership program, OncLive announced today.

COA Says New Care Model Doesn't Go Far Enough

February 13th 2015

The COA has weighed in on a new system of higher value performance for oncologists, saying it is a step in the right direction but needs to be supported by broader reforms.

Radium-223 for Treatment of Prostate Cancer

February 13th 2015

Antiandrogen Resistance With AR-V7 in CRPC

February 13th 2015

Enzalutamide Offers Second Option in Pre-Chemo CRPC

February 13th 2015

Pre-Chemotherapy Abiraterone Acetate in CRPC

February 13th 2015

Integrating CHAARTED Findings Into Prostate Cancer Care

February 13th 2015

CHAARTED Trial Changes Practice in Prostate Cancer

February 13th 2015

ADT in Prostate Cancer: Agonists Versus Antagonists

February 13th 2015

Integrating Molecular Testing Into Urology Practices

February 13th 2015